Once administered, the antibody component binds selectively to the tumor-associated antigens that are overexpressed on the surface of malignant cells, such as HER2 in breast cancer, CD33 in AML, or TROP2 in triple-negative breast cancer (TNBC) [17]. This evidence concerns the gene CD33 and acute myeloid leukemia.